Latest News and Press Releases

Inflammasome inhibitors in combination with GLP-1 agonists have potential to address unmet medical needs of people living with obesity.

ZyVersa's IC 100 blocked microglial NLRP1 inflammasome activation and reduced alpha-synuclein accumulation supporting its potential for Parkinson's Disease

Inflammasome inhibition attenuated inflammation, heart muscle enlargement and fibrosis, and improved heart function in obesity-associated cardiomyopathy.

Alzheimer’s disease (AD), affecting around 6.9 million people in the US, is ranked as the seventh leading cause of death and is the most common cause of dementia among older adults.AD begins with...

ZyVersa looks forward to meeting with investors and potential collaborators at JPM 2025 to discuss our technology, pipeline, and development milestones.

ZyVersa announces progress toward achieving key near-term development milestones and Q3-2024 financials.

Inflammasome-driven inflammation in obesity results in severely damaged pancreatic islets, leading to islet cell loss and metabolic dysfunction.

Obesity treatment needs to go beyond weight loss and address the damaging inflammation leading to life-altering comorbidities.

Newly published data show that obesity leads to progressive brain inflammation that worsens with prolonged obesity and increased age.

ZyVersa discusses trend toward add-on therapy for obesity to address metabolic complications and the role of inflammasome inhibitors on Big Biz Show.